NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Technology Appraisals Committee for re-consideration of Cancer Drugs Fund topics
Terms of Reference and Standing Orders

Terms of reference

General

1. NICE is forming a special Appraisal Committee to accommodate the discussion of an additional number of topics for the reconsideration of drugs funded by the Cancer Drugs Fund. For capacity reasons it is not possible to distribute these topics across the existing 4 Appraisal Committees.

2. The Technology Appraisals Committee for the re-consideration of drugs funded by the CDF (transition) will:

   a. operate as a standing advisory committee of the Board of NICE.
   b. receive, consider and interpret evidence on the clinical effectiveness and cost effectiveness of health technologies referred to it.
   c. develop guidance for the NHS in accordance with the published process and methods guides of the Technology Appraisal programme.
   d. submit its recommendations to the NICE Guidance Executive which will act under delegated powers of the Board in considering and approving the recommendations.

Membership

3. The membership for this Appraisal Committee will be drawn from the 96 members appointed by NICE and shall reflect both the spread of interests and expertise required for the business of the committee and the Institute’s values of equality and diversity.

4. The committee will normally have 24 voting members including the chair.

5. Additional experts may be invited to attend to advise the committee on a topic by topic basis to assist in considering and interpreting the evidence. They will not have voting rights and will not count towards the quorum.

Standing Orders

6. The standing orders for this Committee remain unchanged from those
published for the existing Appraisal Committees.

Date: January 2016
Review date: Not applicable